|
2023
|
Invention
|
Medication for inhibiting dna-pkcs.
A method for treating a tumor or cancer by means of a treatm... |
|
2022
|
Invention
|
Drug for inhibiting adipose cell differentiation and insulin resistance.
The present invention p... |
|
|
Invention
|
Disinfectant. Provided is a novel disinfectant, comprising: an active agent, an auxiliary agent, ... |
|
2020
|
Invention
|
Molecular design of recombinant protein drug.
Provided is a mutant of an endostatin. The mutant ... |
|
2018
|
Invention
|
Medication for inhibiting dna-pkcs. A method for treating a tumor or cancer by means of a treatme... |
|
2017
|
Invention
|
Method for inhibiting lymphangiogenesis by administration of an inhibitor of the cxcl12 pathway. ... |
|
|
Invention
|
Pegylated endostatin analogue and application thereof. The present invention provides a polyethyl... |
|
2016
|
Invention
|
Molecular design of recombinant protein drug. Provided is a mutant of an endostatin. The mutant h... |
|
2015
|
Invention
|
Drug for inhibiting adipose cell differentiation and insulin resistance. Provided in the present ... |
|
2014
|
Invention
|
Tumor biomarker.
A method of determining whether a subject has cancer or has a risk of getting c... |
|
|
Invention
|
Tumor biomarker. A method of determining whether a subject has cancer or has a risk of getting ca... |
|
2013
|
Invention
|
Method and medicament for inhibiting lymphangiogenesis.
The present invention provides a method ... |
|
2012
|
Invention
|
Endostatin mutants with mutations at atp binding sites. The present invention discloses a new ant... |
|
|
Invention
|
Vascular endothelial myostatin mutant that mutates at atp binding sites. Discloses is a new medic... |
|
|
Invention
|
Methods and compositions for enhancing the uptake of therapeutic agents by target cells. The pres... |
|
|
Invention
|
Method and composition for enhancing target cells uptake of therapeutic agents. The present inven... |
